- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (718)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (628)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (64)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (898)
- Research (392)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (604)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (322)
- Symptoms (184)
- Treatment (1776)
MD Anderson is first in Texas to be accredited to train tobacco treatment specialists
2 minute read | Published August 08, 2017
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on August 08, 2017
Since 2006, MD Anderson’s Tobacco Treatment Program (TTP) has been providing tobacco cessation services to patients and employees seeking to quit or decrease their tobacco use. Soon, the institution’s tobacco cessation expertise will be available to any health care professional interested in treating tobacco users.
MD Anderson recently was accredited to offer official training and certification by the Association for the Treatment of Tobacco Use
and Dependence, an organization of providers dedicated to the promotion of and increased access to evidence-based tobacco treatment. With this designation, MD Anderson’s Certified Tobacco Treatment Training Program (CTTTP) becomes the only accredited program in Texas, and one of only 15 in the nation.
There’s a particular need for such programs in Texas, where current smoking rates remain above 15% and an estimated 28,000 adults die each year from tobacco use – the single largest preventable cause of death in the U.S.
“Our program will offer the highest quality tobacco-treatment specialist training using the latest evidence-based tobacco cessation research and treatment strategies,” says Paul Cinciripini, Ph.D., chair of Behavioral Science and director of the Tobacco Treatment Program. “The training will include knowledge gained from MD Anderson investigator-initiated research trials and highly specialized clinical experience.”
Interdisciplinary health care providers and public health professionals will be trained to deliver a high-intensity, evidence-based, cognitive-behavioral treatment for nicotine dependence. This represents an expansion of the TTP approach, which was designed to leverage MD Anderson’s expertise and increase capacity in order to provide best-practice cessation services in Texas and beyond.
Faculty and professionals from the TTP will provide clinical expertise in smoking cessation counseling and pharmacotherapy, and the EndTobacco program staff will offer their expertise in programmatic implementation and logistical support.
The EndTobacco program is an initiative of MD Anderson’s cancer prevention and control platform, which is part of the institution’s Moon Shots Program™, an ambitious effort to reduce cancer deaths by more rapidly developing and implementing advances in prevention, early detection and treatment.
The CTTTP’s first four-day training course will be Aug. 15-18, with subsequent courses scheduled quarterly. Find more information here.
Topics
Prevention
We follow an evidence-based approach combined with our many years of testing and experience, which represents an effective balance producing an innovative and cutting-edge clinical approach. Unique to our program is our ability to share specific expertise in working with cancer patients and those with mental health disorders.
Maher Karam-Hage, M.D., professor of Behavioral Science and associate medical director of the TTP